Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy.’ The study aims to evaluate the efficacy of tarlatamab, a novel drug, in prolonging overall survival compared to standard chemotherapy treatments in patients with relapsed small cell lung cancer.
The intervention being tested is tarlatamab, administered as an intravenous infusion. It is compared against standard of care chemotherapy drugs, including Lurbinectedin, Topotecan, and Amrubicin, to determine its effectiveness in improving patient outcomes.
The study follows a randomized, parallel assignment design without masking, focusing primarily on treatment. This design ensures that participants are randomly assigned to either the experimental group receiving tarlatamab or the control group receiving standard chemotherapy, allowing for a clear comparison of outcomes.
The study began on May 31, 2023, and is currently active but not recruiting. The last update was submitted on June 26, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results, which could impact market dynamics.
Amgen’s ongoing study could significantly influence its stock performance and investor sentiment, especially if tarlatamab proves to be more effective than existing treatments. This development is particularly relevant in the competitive oncology market, where advancements can lead to substantial shifts in market share.
The study is ongoing, with further details available on the ClinicalTrials portal.